Dr. Chagpar on Novel Agents for Neoadjuvant TNBC Treatment скачать в хорошем качестве

Dr. Chagpar on Novel Agents for Neoadjuvant TNBC Treatment

Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, discusses novel agents for neoadjuvant triple-negative breast cancer (TNBC) treatment. TNBC represents about one-fifth of all breast cancers, Chagpar explains. Historically, it has been associated with a poor prognosis. As patients with TNBC respond well to neoadjuvant chemotherapy, there has been a number of clinical trials looking at novel agents in this subset of patients. For example, platinum-based agents seem to work well in TNBC, she says. Patients with TNBC tend to have a high rate of tumor infiltrating lymphocytes, Chagpar explains, so this is a potentially exciting target for immunotherapy. Clinical trials have shown immunotherapy works well in heavily pre-treated patients with metastatic breast cancer, and Chagpar believes an ongoing trial looking at neoadjuvant immunotherapy in early-stage TNBC has the potential to change disease management for these patients.